Sign in
CompletedPhase 2

An Innovative Chinese Herbal Formula for the Treatment of Gout

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
80 people enrolled
Started
11 Oct 2022
Ended
27 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HKIIM-KU formula
  • Placebo
Record updated
27 July 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patient meeting the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2015 gout classification criteria (met sufficient criterion* or total score ≥8)
  • History of >=1 self-reported flare of gouty arthritis within 12 months prior to randomization
  • Agree to undergo blood test and willing to complete questionnaires and take medications as scheduled; and
  • Agree to participate in the study and provide written informed consent. (for those illiterate subjects, their family member can sign the consent form upon subject's agreement) Note: * Sufficient criterion = Presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus

Who cannot take part

  • Use of urate-lowering drugs within 2 weeks prior to screening
  • Known use of oral/injectable corticosteroids or other Chinese herbal medicine for treating gout within 1 month prior to screening
  • Ongoing acute gout arthritis flare at screening or within 2 weeks prior to screening
  • History of >4 flares overall in the 12 months prior to screening
  • Present of tophi or known history of kidney stones
  • Known history of any serious diseases such as severe kidney and liver impairments, autoimmune disease, thyroid disease, Hodgkin's disease, lymphoma, severe mental disorders and leukemia
  • Known presence or suspicion of acute infectious disease
  • Known history of malignancy within the past 5 years
  • Known allergic to the drug used in this study
  • Liver-kidney yin deficiency pattern according to Chinese medicine theory
  • Polyarticular gouty arthritis involving more than 4 joints
  • Severe deformity, stiffness and labor loss of patients with advanced arthritis
  • Known rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
  • Documented pregnant or lactation
  • Subjects participating in other clinical studies at the same time

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide annually.

Read full original descriptionShow less

The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.

Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.

The 2 groups in the trial

  • HKIIM-KU formulaTreatment being tested

    Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.

  • PlaceboPlacebo, for comparison

    Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of an Innovative Chinese Herbal Formula for the Treatment of Gout: A Double-blind, Randomized, Placebo-Controlled Trial
Record updated
27 July 2026